Tecnología Médica
Tecnología Médica
CollPlant to trial 3D bioprinted breast implants in breakthrough animal study
01/04/2022 -
Regenerative medicine specialist CollPlant (NASDAQ: CLGN) has revealed that the 3D bioprinted breast tissues it’s developing are set to enter animal trials in the very near future. Alongside the release of its FY 2021 results, which show that it generated $15.6 million in revenue, 155.7% more than the $6.1 million it reported in FY 2020, CollPlant announced that its bioprinted implants will enter in-vivo testing from Q2 2022.